Clinical implications of androgen synthesis via 5α-reduced precursors

Endocrine Development

Volumn 13, Issue , 2008, Pages 55-66

  Ghayee, H ^a   Auchus, R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; HUMAN; MARSUPIAL; METABOLIC DISORDER; METABOLISM; REVIEW;

ANDROGENS; ANIMALS; DIHYDROTESTOSTERONE; HUMANS; MACROPODIDAE; METABOLIC DISEASES; MODELS, BIOLOGICAL; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 48949099915     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000134780     Document Type: Review

References (58)

1. Griffin JE, Wilson JD: Disorders of the testes and the male reproductive tract; in Larson PR, et al. (eds): Williams Textbook of Endocrinology, W.B. Saunders, 2003, pp 709-770.
2. Bruchovsky N, Wilson JD: The intranuclear binding of testosterone and 5α-androstan-17β-ol-3-one by rat prostate. J Biol Chem 1968;243:5953-5960.
3. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC, Wilson JD: Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974;291:944-949.
4. Moore RJ, Wilson JD: Steroid 5α-reductase in cultured human fibroblasts. Biochemical and genetic evidence for two distinct enzyme activities. J Biol Chem 1976;251:5895-5900.
5. Andersson S, Berman DM, Jenkins EP, Russell DW: Deletion of a steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 1991;354:159-161.
6. 5 augments the 17,20 lyase activity of human P450c17 without direct electron transfer. J Biol Chem 1998;273:3158-3165.
7. 5 steroidogenic pathway. J Clin Endocrinol Metab 2003;88:3762-3766.
8. White PC, Speiser PW: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245-291.
9. Moisan AM, Ricketts ML, Tardy V, Desrochers M, Mebarki F, Chaussain JL, Cabrol S, Raux-Demay MC, Forest MG, Sippell WG, Peter M, Morel Y, Simard J: New insight into the molecular basis of 3β-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene in eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. J Clin Endocrinol Metab 1999;84:4410-4425.
10. Bongiovanni AM: The adrenogenital syndrome with deficiency of 3β-hydroxysteroid dehydrogenase. J Clin Invest 1962;41:2086.
11. 4-3- ketosteroid 5α-oxidoreductase of rat prostate. J Biol Chem 1971;246: 2584-2593.
12. A receptors. J Neuroendocrinol 1995;7:171-177.
13. Wilson JD, Shaw G, Leihy ML, Renfree MB: The marsupial model for male phenotypic development. Trends Endocrinol Metab 2002;13:78-83.
14. Wilson JD, Leihy MW, Shaw G, Renfree MB: Unsolved problems in male physiology: studies in a marsupial. Mol Cell Endocrinol 2003;211:33-36.
15. Wilson JD, George FW, Shaw G, Renfree MB: Virilization of the male pouch young of the tammar wallaby does not appear to be mediated by plasma testosterone or dihydrotestosterone. Biol Reprod 1999;61:471-475.
16. Shaw G, Renfree MB, Leihy MW, Shackleton CH, Roitman E, Wilson JD: Prostate formation in a marsup ial is mediated by t he t esticular androgen 5α-androstane-3α,17β-diol. Proc Natl Acad Sci USA 2000;97:12256-12259.
17. Walsh PC, Wilson JD: The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 1976;1093-1097.
18. Biswas MG, Russell DW: Expression cloning and characterization of oxidative 17β- and 3α-hydroxysteroid dehydrogenases from rat and human prostate. J Biol Chem 1997;272:15959-15966.
19. Wilson JD, Auchus RJ, Leihy MW, Guryev OL, Estabrook RW, Osborn SM, Shaw G, Renfree MB: 5α-androstane-3α,17α-diol is formed in tammar wallaby pouch young testes by a pathway involving 5α-pregnane-3α, 17α-diol-20-one as a key intermediate. Endocrinology 2003;144:575-580.
20. Jez JM, Penning TM: The aldo-keto reductase (AKR) superfamily: an update. Chem Biol Interact 2001;130-132:499-525.
21. Eckstein B, Borut A, Cohen S: Metabolic pathways for androstanediol formation in immature rat testis microsomes. Biochim Biophys Acta 1987;924:1-6.
22. Chase DJ, Payne AH: Changes in Leydig cell function during sexual maturation in the mouse. Biol Reprod 1983;29:1194-1200.
23. Sheffield JW, O'Shaughnessy PJ: Testicular steroid metabolism during development in the normal and hypogonadal mouse. J Endocrinol 1988;119:257-264.
24. Ge RS, Hardy MP: Variation in the end products of androgen biosynthesis and metabolism during postnatal differentiation of rat Leydig cells. Endocrinology 1998;139:3787-3795.
25. Ge RS, Hardy DO, Catterall JF, Hardy MP: Opposing changes in 3α-hydroxysteroid dehydrogenase oxidative and reductive activities in rat leydig cells during pubertal development. Biol Reprod 1999;60:855-860.
26. Frungieri MB, Gonzalez-Calvar SI, Bartke A, Calandra RS: Influence of age and photoperiod on steroidogenic function of the testis in the golden hamster. Int J Androl 1999;22:243-252.
27. Carmichael R, Belanger A, Cusan L, Seguin C, Caron S, Labrie F: Increased testicular 5α-androstane-3α,17α-diol formation induced by treatment with [D-Ser (TBU) 6, des-Gly-NH2(10)] LHRH ethylamide in the rat. Steroids 1980;36:383-391.
28. Mahendroo MS, Wilson JD, Richardson JA, Auchus RJ: Steroid 5α-reductase 1 promotes 5α-androstane-3α,17α-diol synthesis in immature mouse testes by two pathways. Mol Cell Endocrinol 2004;222:113-120.
29. Wilson JD, Griffin JE, Russell DW: Steroid 5α-reductase 2 deficiency. Endocr Rev 1994;14:577-593.
30. Siiteri PK, Wilson JD: Testosterone formation and metabolism during male sexual differentiation in the human embryo. J Clin Endocrinol Metab 1974;38:113-125.
31. 21 steroids are substrates for human cytochrome P450c17. Arch Biochem Biophys 2003;418:151-160.
32. 5 in the biosynthesis of androgens by human P450c17. Arch Biochem Biophys 1995;317:343-347.
33. 5:endocrinological and mechanistic implications. Biochem J 1995;308:901-908.
34. Auchus RJ: The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 2004;15:432-438.
35. Backstrom T, Andersson A, Baird DT, Selstam G: The human corpus luteum secretes 5α-pregnane-3,20-dione. Acta Endocrinol (Copenh) 1986;111:116-121.
36. Milewich L, Mendonca BB, Arnhold I, Wallace AM, Donaldson MD, Wilson JD, Russell DW: Women with steroid 5α-reductase 2 deficiency have normal concentrations of plasma 5α-dihydroprogesterone during the luteal phase. J Clin Endocrinol Metab 1995;80:3136-3139.
37. Yokoi H, Tsuruo Y, Miyamoto T, Ishimura K: Steroid 5α-reductase type 1 immunolocalized in the adrenal gland of normal, gonadectomized, and sex hormone-supplemented rats. Histochem Cell Biol 1998;109:127-134.
38. Hanley NA, Arlt W: The human fetal adrenal cortex and the window of sexual differentiation. Trends Endocrinol Metab 2006;17:391-397.
39. Peterson RE, Imperato-McGinley J, Gautier T, Shackleton C: Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. N Engl J Med 1985;313:1182-1191.
40. Shackleton C, Malunowicz E: Apparent pregnene hydroxylation deficiency (APHD): seeking the parentage of an orphan metabolome. Steroids 2003;68:707-717.
41. Miller WL: Congenital adrenal hyperplasia. N Engl J Med 1986;314:1321-1322.
42. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, Jabs EW, Mendonca BB, Fujieda K, Miller WL: Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004;36:228-230.
43. Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, Chalder SM, Borucka-Mankiewicz M, Hauffa BP, Malunowicz EM, Stewart PM, Shackleton CH: Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004;363:2128-2135.
44. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, Jabs EW, Van Vliet G, Sack J, Flück CE, Miller WL: Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005;76:729-749.
45. Yanagibashi K, Hall PF: Role of electron transport in the regulation of the lyase activity of C-21 side-chain cleavage P450 from porcine adrenal and testicular microsomes. J Biol Chem 1986;261:8429-8433.
46. Geller DH, Auchus RJ, Mendonça BB, Miller WL: The genetic and functional basis of isolated 17,20 lyase deficiency. Nat Genet 1997;17:201-205.
47. Auchus RJ, Miller WL: Molecular modeling of human P450c17 (17α-hydroxylase/17,20-lyase): Insights into reaction mechanisms and effects of mutations. Mol Endocrinol 1999;13:1169-1182.
48. Shackleton C, Marcos J, Arlt W, Hauffa BP: Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): A disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype. Am J Med Genet A 2004;129:105-112.
49. Homma K, Hasegawa T, Nagai T, Adachi M, Horikawa R, Fujiwara I, Tajima T, Takeda R, Fukami M, Ogata T: Urine s teroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor p athway to dihydrotestosterone. J Clin Endocrinol Metab 2006;91:2643-2649.
50. Whorwood CB, Ueshiba H, del Blazo P: Plasma levels of C19 steroid glucuronides in pre-menopausal women with non-classical congenital adrenal hyperplasia. J Steroid Biochem Mol Biol 1992;42:211-221.
51. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
52. Arlt W, Justl H-G, Callies F, Reincke M, Hubler D, Oettel M, Ernst M, Schulte HM, Allolio B: Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab 1998;83:1928-1934.
53. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z: Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 1992;327:157-162.
54. Rosenfield RL, Barnes RB, Ehrmann DA: Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1994;79:1686-1692.
55. Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-623.
56. Thompson DL, Horton N, Rittmaster RS: Androsterone glucuronide is a marker of adrenal hyperandrogenism in hirsute women. Clin Endocrinol (Oxf) 1990;32:283-292.
57. Falsetti L, Rosina B, De Fusco D: Serum levels of 3α-androstanediol glucuronide in hirsute and non hirsute women. Eur J Endocrinol 1998;138:421-424.
58. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W: Beyond adrenal and ovarian androgen generation: Increased peripheral 5α-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2760-2766.